COVID-19

For more information on COVID-19, visitor restrictions, and vaccine updates, click here.

Clinical Trials

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and research nurses carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study. Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure Taking Part in Cancer Treatment Research Studies to help you understand the details of clinical trials.

To learn more about our ongoing trials for cancer treatment and prevention, please contact Tina Bergner, RN, BSN, OCN, oncology clinical research coordinator, at 609-537-7042 or e-mail her at [email protected] for more information.

Active clinical trials currently being offered:

Brain Studies

3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

Molecular and biochemical characterization of malignant and metastatic brain tumors

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Genomically-guided treatment trial in brain metastasis

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma With Elevated Mutational Burden

Testing the Use of the Immunotherapy Drugs, Ipilimumab and Nivolumab, Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Navid Redjal, MD, FAANS, Director, Neurosurgical Oncology
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024
Liver and Pancreas Studies

Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT

Circulating Biomarkers and Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FACS, Hepato-pancreato-biliary Surgeon, Medical Director, Capital Health Cancer Center
  • Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042
Gynecology Studies

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

Lung Studies

A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC

SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer

  • Study Information: NCT04155034; NCTN # S1827 (https://clinicaltrials.gov/ct2/show/NCT04155034)
  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Principal Investigator: Shirnett Williamson, MD, DABR, Radiation Oncologist, Director, Radiation Oncology Services
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

Other Organs

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

Cancer Tissue Biorepository

  • Study Information: NCT N/A
  • Sponsor: Capital Health
  • Principal Investigator: Krister Jones, MD, Pathologist, Chief, Cytopathology and Microbiology
  • Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042
Urogenital Studies

Diagnostic Markers in Patients with Bladder Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Eric Mayer, MD, Urologic Oncology Surgeon, Director, Urologic Robotic Surgery
  • Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042

Stereotactic Body Radiation Therapy or Intesity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer

Other resources:

Capital Health Earns National Distinction as a Top Performer in Patient Experience

Capital Health Medical Center – Hopewell has been named a 2021 Guardian of Excellence Award® winner by Press Ganey, the national leader in health care consumer and workforce engagement. Press Ganey recognizes Capital Health as a top-performing health care organization achieving the 95th percentile or above for performance in patient experience. 
 

Capital Health Medical Group Introduces New Primary Care Office in West Windsor, Expands Access to Medical Care in Greater Mercer and Middlesex Counties

Capital Health Medical Group, a network of more than 500 physicians and other clinicians who offer primary and specialty care, has opened a new primary care office in West Windsor. The office is new in addition to the new primary care office that opened only a few weeks ago in nearby East Windsor. 

Capital Health Joins the HHS Perinatal Improvement Collaborative to Improve Outcomes for Mothers and Babies

Capital Health Medical Center – Hopewell is participating in the U.S. Department of Health and Human Services (HHS) Perinatal Improvement Collaborative, a large-scale, data-driven collaborative of 200+ leading hospitals caring for diverse populations in all 50 states. 

View All News
View All Events